UroGen Pharma Ltd (URGN) - Total Assets
Based on the latest financial reports, UroGen Pharma Ltd (URGN) holds total assets worth $253.69 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check URGN capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
UroGen Pharma Ltd - Total Assets Trend (2013–2025)
This chart illustrates how UroGen Pharma Ltd's total assets have evolved over time, based on quarterly financial data. Explore how much of UroGen Pharma Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
UroGen Pharma Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
UroGen Pharma Ltd's total assets of $253.69 Million consist of 92.8% current assets and 7.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 55.3% |
| Accounts Receivable | $33.08 Million | 16.5% |
| Inventory | $16.46 Million | 8.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how UroGen Pharma Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see URGN stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: UroGen Pharma Ltd's current assets represent 92.8% of total assets in 2025, a decrease from 97.6% in 2013.
- Cash Position: Cash and equivalents constituted 55.3% of total assets in 2025, down from 94.2% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 16.5% of total assets.
UroGen Pharma Ltd Competitors by Total Assets
Key competitors of UroGen Pharma Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
UroGen Pharma Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.69 | 5.65 | 7.37 |
| Quick Ratio | 4.28 | 5.47 | 7.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $186.83 Million | $195.18 Million | $121.44 Million |
UroGen Pharma Ltd - Advanced Valuation Insights
This section examines the relationship between UroGen Pharma Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 19.27 |
| Latest Market Cap to Assets Ratio | 7.15 |
| Asset Growth Rate (YoY) | -29.8% |
| Total Assets | $200.46 Million |
| Market Capitalization | $1.43 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values UroGen Pharma Ltd's assets at a significant premium (7.15x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: UroGen Pharma Ltd's assets decreased by 29.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for UroGen Pharma Ltd (2013–2025)
The table below shows the annual total assets of UroGen Pharma Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $200.46 Million | -29.84% |
| 2024-12-31 | $285.71 Million | +60.23% |
| 2023-12-31 | $178.31 Million | +31.48% |
| 2022-12-31 | $135.62 Million | +13.26% |
| 2021-12-31 | $119.75 Million | -1.85% |
| 2020-12-31 | $122.00 Million | -39.72% |
| 2019-12-31 | $202.39 Million | +95.43% |
| 2018-12-31 | $103.56 Million | +37.07% |
| 2017-12-31 | $75.55 Million | +227.68% |
| 2016-12-31 | $23.06 Million | +18.91% |
| 2015-12-31 | $19.39 Million | +344.83% |
| 2014-12-31 | $4.36 Million | +35.16% |
| 2013-12-31 | $3.23 Million | -- |
About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder… Read more